A systematic review of medical evidence has determined drug-eluting stents outperform bare-metal stents for revascularization of chronic total occlusions. The researchers found coated stents reduce restenosis and revascularization, offering a safe approach with the same side effects as a BMS. Full results are available in the February issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of the Society for Cardiovascular Angiography and Interventions.This approach integrates the advantages of small molecules and antibodies, said Cheng, who has contributed to the use of aptamers as targeting molecules for drug delivery. This is the first study to integrate aptamers and liposomes.
Our results confirm that treatment of total coronary occlusions with DES is associated with significant reductions in angiographic and clinical restenosis compared with BMS, said Dr. Brilakis. Analysis of the angiographic results of the studies revealed less restenosis with DES compared with BMS implantation . A 6 to 12 months target lesion revascularization and were consistently lower among patients treated with DES . In a 19-month follow-up, the cumulative incidence of death or stent thrombosis was similar between DES and BMS in all studies
To determine the performance of DES in CTO implementation, Emmanouil Brilakis, MD, PhD, FSCA – VA North Texas Health Care System and University of Texas Southwestern Medical Center at Dallas – and colleagues conducted a systematic review of literature published in the online database and Heart company websites.
The researchers found 17 published studies that have reported results for sirolimus-or paclitaxel-eluting stents and BMS implantation for coronary occlusions.